How dorsaVi’s Real-Time AI Sensors Are Winning Elite Sport and European Clinical Deals
dorsaVi has secured significant commercial and clinical milestones with new elite sports and European clinical partnerships, showcasing its advanced real-time AI sensor technology.
- ViMove+ platform expands to 120+ US physical therapy sites
- New commercial project with ESPN injury expert Dr. Chirag Patel
- dorsaVi sensors selected for European SEROMA study on Axial Spondyloarthritis
- Proprietary Onboard Sensor Processing enables real-time AI analytics on-device
- Emerging opportunities in pharma trials, elite sport, robotics, and European regulatory markets
Expanding Clinical and Commercial Footprint
dorsaVi Limited (ASX:DVL) has announced a series of strategic commercial and clinical advancements that mark a notable acceleration in its market presence. The company’s ViMove+ wearable sensor platform now operates across more than 120 active physical therapy sites in the United States, with ongoing expansion into new states. This growth is supported by integration with the Select Hub platform, streamlining deployment and embedding the technology deeper into clinical workflows.
Alongside this network expansion, dorsaVi has initiated trials with additional physiotherapy groups on the US East Coast, reinforcing the platform’s clinical utility and adoption potential across diverse practice environments.
Elite Sport Partnership with Dr. Chirag Patel
European Clinical Breakthrough with SEROMA
In Europe, dorsaVi’s sensors have been selected for the SEROMA project, a pivotal clinical study investigating objective outcome measures for Axial Spondyloarthritis (axSpA), a chronic inflammatory spinal condition. The study spans six European sites and involves leading rheumatologists and three global pharmaceutical companies. This selection follows a competitive review and underscores dorsaVi’s clinical sensor technology expertise and strong intellectual property position.
The SEROMA project aims to replace the outdated BASMI index with a validated, sensor-based alternative, which could become the new gold standard for assessing disease progression. This breakthrough has significant implications for pharmaceutical trials and regulatory approval processes under FDA and EMA frameworks.
Technology Edge: Intelligence at the Ultra Edge
Central to both the elite sport and clinical agreements is dorsaVi’s proprietary Onboard Sensor Processing (OSP) technology. Unlike traditional wearables that passively collect data for cloud analysis, dorsaVi’s sensors perform real-time AI inference directly on the device. This capability enables immediate, clinically meaningful metrics without latency, a critical advantage in fast-paced environments such as elite sports and dispersed clinical trials.
Further enhancing this edge is dorsaVi’s investment in neuromorphic computing and Resistive RAM (RRAM) technology, developed in collaboration with ITRI and NTU. These advancements promise ultra-low power, high-speed AI processing in wearable form factors, positioning dorsaVi to extend its platform capabilities into continuous remote patient monitoring, precision medicine, and occupational health.
Emerging Horizons: Robotics and Regulatory Alignment
Beyond healthcare and sport, dorsaVi is eyeing the burgeoning humanoid robotics market, projected to reach US$372 billion by 2034. The company’s clinically validated biomechanical datasets; particularly foot, ankle, and spinal movement metrics; are increasingly valuable for training and validating locomotion models in next-generation robots.
Moreover, dorsaVi’s involvement in European clinical research aligns with emerging AI and robotics regulatory frameworks, enhancing its credibility and market access in these evolving sectors.
Bottom Line?
dorsaVi’s real-time AI sensor technology is carving out leadership in elite sport, clinical research, and emerging robotics, setting the stage for broader market impact.
Questions in the middle?
- How quickly will dorsaVi’s new elite sport and clinical modules translate into significant recurring revenue?
- What regulatory hurdles remain for widespread adoption of sensor-based outcome measures in pharma trials?
- Can dorsaVi’s technology maintain its competitive edge as neuromorphic computing matures?
